Moderna Stock Rises After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.

Moderna defied expectations of a Covid-revenue slowdown on Friday as the drugmaker delivered strong first-quarter results fueled by a surge in international vaccine sales. One trend underscored growth in the quarter: higher Covid-19 vaccine sales, largely due to long-term government partnerships in international markets. This marks a shift from previous quarters, when Moderna cautioned that its Covid vaccine revenue was slipping.